Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | 0.00% | 0.00% | -68.28% |
05:15pm | Antibe Therapeutics Inc. Announces Board Resignations | CI |
Apr. 19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 15.64M 11.4M |
---|---|---|---|---|---|
Net income 2024 * | -19M -13.85M | Net income 2025 * | -15M -10.93M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-1.02
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.06% |
Current month | -34.44% | ||
1 month | -31.40% | ||
3 months | -67.93% | ||
6 months | -54.62% | ||
Current year | -68.28% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Legault
CEO | Chief Executive Officer | 66 | 09-05-04 |
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
CHM | Chairman | 58 | 20-11-23 |
Director/Board Member | 50 | 20-11-23 | |
Yung Wu
BRD | Director/Board Member | - | 16-07-17 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.44M | |
-1.77% | 105B | |
+3.25% | 97.5B | |
+1.86% | 22.19B | |
-16.64% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.96% | 14.52B | |
+5.09% | 14.09B | |
+22.38% | 10.99B |
- Stock Market
- Equities
- ATE Stock